Skip to main content
. Author manuscript; available in PMC: 2018 Oct 9.
Published in final edited form as: Pharmacol Res. 2017 Dec 2;129:365–374. doi: 10.1016/j.phrs.2017.11.033

Table 1: Natural products under various phases of clinical development in different malignancies.

Below table showing the different natural products and their targets which are under various phases of drug development/ clinical trials.

Natural Agent Target Indication/status
BET inhibitors: l-BET-762 BET (bromodomain and extra terminal domain) proteins Acute myeloid leukemia/Phase 1
Breast adenocarcinoma/Phase 2
Breast cancer/Phase 1
Colorectal cancer/Phase 1
Multiple myeloma/Phase 1
Neuroblastoma/Phase 1
Non-small cell lung cancer/Phase 1
Trichostatin, Histone deacetylase Metastatic melanoma/phase 1
Topotecan Topoisomerase I Cervical carcinoma/Approved
Statins: atorvastatin HMG-CoA reductase Acute myeloid leukemia/Phase 2
Acute lymphocytic leukemia/Phase 2
Rho kinase inhibitors Rho-associated kinases ROCK1 and ROCK2 Exfoliative glaucoma/Phase 2
Glaucoma/Phase 2
Ocular hypertension/Phase 2
Open-angle glaucoma/Phase 2
Genistein, Protein tyrosine kinase (PTK) Neuroblastoma/Phase 2
Germ cell tumor/Phase 2
Prostate cancer/Phase 2